Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLB1001 in Met-positive Advanced NSCLC
NCT02896231Phase 1Completed
- Sponsor
- Beijing Pearl Biotechnology Co., Ltd.
- Start
- Apr 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vebreltinib in non-small cell lung cancer (NSCLC), sponsored by Beijing Pearl Biotechnology Co., Ltd. Primary endpoint: Percentage of participants with dose-limiting toxicities at 2 years. Started Apr 2016; status: completed.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02896231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02896231.